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Introduction: Over the last decade, global health policies and different research areas 
have focused on the relevance and impact of medicine shortages. Published studies 
suggest there have been difficulties with access to medicines since the beginning of the 
20th century, and there have been advances in our understanding and management of 
the problem since then. However, in view of global and regional health care concerns with 
shortages, we believe this phenomenon needs to be characterized and described more 
fully regarding the types of medicines affected, possible causes, and potential strategies 
to address these. The aim of this scoping review was to identify, compare if possible, and 
characterize the recent literature regarding the situation of medicines shortages between 
countries, and provide different perspectives, including a global context and national 
approaches.
Methodology: A scoping study presented as a narrative review of the situation and 
findings principally based on published articles.
Results: Based on the reported cases in the literature, a typology of medicines shortage 
and supply interruption episodes and their causes were proposed; national approaches 
to notify and manage the medicines shortages cases were described and classified by 
update frequency; principal differences between market and supply chain management 
perspectives of the situation were identified and global and countries’ perspectives were 
described.
Conclusion: Policy makers require solutions that prevent those cases in which the 
population’s health is affected by episodes of medicine shortages and/or interruption 
in the supply chain. There is also a need to generate a glossary related to logistics 
management and the availability of medicines which will be useful to understand and 
overcome shortages. In addition, recognize that potential solutions are not only related 
with actions linked to research, development and innovation, but much wider. Overall, we 
believe this article can act as a basis for future discussions in this important area.
Keywords: medicine shortages, medicine access, pharmaceutical policy, medicine supply, South America, 
Europe, North America, Western Asia
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INTRODUCTION
The World Health Organization (WHO) defined “access to 
medicines” as a multidimensional problem in view of the rising 
prices of new medicines and persisting problems of medicine 
shortages among others (World Health Organization, 2018). 
Other concerns include out-of-pocket payments, which are 
especially important in lower- and middle-income countries 
(LMICs) where expenditure of medicines can be up to 70% of 
total health care expenditure and potentially catastrophic for 
patients and their families if they become ill (Cameron et al., 2009; 
Ofori-Asenso and Agyeman, 2016; World Health Organization, 
2018). However, this is outside the scope of this article, which 
principally deals with issues of shortages of medicines.
The last WHO Director-General’s report included a variety of 
terms on global medicine shortages such as “shortage,” “scarcity” 
(only in the Spanish version), and “stock outs” (only in the 
English version) that demand a comprehensive approach across 
countries (World Health Organization, 2018). Consequently, 
there is an urgent need to develop a set of terminologies related 
to the problems identified by countries regarding the continual 
availability of essential medicines.
There are different situations leading to out of stock of 
medicines. Some of them can be solved without causing obstacles 
to health care provision or in the availability of the best therapeutic 
option, whereas others may require additional efforts and ways 
to overcome affected health conditions. There have been several 
important efforts to document countries’ experiences and potential 
ways forward to address concerns with medicine shortages. The 
study of ISAGS UNASUR published in 2017 characterized and 
analyzed the situation among eight South American countries: 
Bolivia, Chile, Colombia, Ecuador, Paraguay, Peru, Venezuela, 
and Uruguay (ISAGS, 2017). In 2018, Bochenek et al. (2018) 
systematically characterized, compared, and evaluated current 
measures, as well as legislative and organizational frameworks, 
to address medicines shortages among a wide range of European 
and Western Asian countries. These included 20 countries of the 
European Union (EU) and the European Free Trade Association 
(EFTA)—Austria, Belgium, Croatia, the Czech Republic, Estonia, 
France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, and 
Switzerland. In addition, eight non-EU/EFTA countries: Albania, 
Azerbaijan, Israel, Kosovo, Montenegro, Republic of Srpska 
(Bosnia and Herzegovina), Serbia, and Turkey.
Both publications involving descriptions from different regions 
of the world with similar findings about formal definitions as well 
as strategies that had been developed to prevent or mitigate against 
medicine shortages. Both publications emphasized the urgent need 
to explore further the phenomena to identify mechanisms which 
introduce possible solutions for situations affected by medicine 
shortages, as well as facilitate the monitoring and assessing of signals 
and subsequent actions. However, there is a need to consolidate 
current findings to provide additional direction given current 
concerns, building on the experiences of other countries including 
Australia, Canada and the United States, as well as more recent 
research findings (Gupta and Huang, 2013; The Society of Hospital 
Pharmacists of Australian, SHPA, 2017; Videau et al., 2019).
Learning from other countries’ experiences should not be 
underestimated or underutilized in shaping local or national 
pharmaceutical policies (Godman et al., 2010; Gupta and Huang, 
2013; Godman et al., 2014; Moon et al., 2014; Godman et al., 
2015; Moorkens et al., 2017; The Society of Hospital Pharmacists 
of Australian, SHPA, 2017; Godman et al., 2018; Kwon et al., 
2018; Videau et al., 2019). Lessons can be drawn from cross-
country comparisons, even if a given country’s characteristics 
do not perfectly correspond in terms of geographical location, 
size, demography, economy, or type of health care system. 
Consequently, the objectives of this article are to consolidate 
current findings as well as characterize and describe more fully 
the situation across continents to provide further evidence about 
the types of affected medicines, identified causes, and potential 
strategies to address shortages. Subsequently, use the findings to 
provide suggestions to address this important topic.
MATERIALS AND METHODS
The design of this study is a scoping review. Scoping reviews have 
been useful to describe broad topic and provide an overview 
of diverse literature, including different study designs and 
methodologies, both widely available and gray scientific articles 
and reports (Pham et al., 2015).
Previous efforts have helped identify the main characteristics 
to describe the medicine shortage situation including potential 
definitions, general characteristics of the problem, description of 
information systems, potential and perceived causes of shortages, 
and implemented solutions (UNASUR, 2014; De Weerdt et al., 
2015a; De Weerdt et al., 2015b; Pauwels et al., 2015; de Weerdt 
et al., 2017; Nurse-Findlay et al., 2017; Bochenek et al., 2018). We 
have built on this including the studies of Bochenek et al. (2018) 
and ISAGS (2017).
Full information on the content of the ISAGS survey form, 
including all the detailed questions which were posed in study on 
South American countries, can be found in the Supplementary 
Material to this paper. Likewise, detailed information on the 
content of the survey performed in European and Western 
Asian countries can be found in the Supplementary Material 
to the published study of Bochenek et al. Both surveys asked 
about existence of definitions of shortages of medicines, general 
characteristics of the problem, description of information 
systems, groups of medicines in shortage and particular 
molecules, potential and perceived causes of shortages, existence 
of processes, protocols and indicators to address shortages when 
they appear and to monitor their dynamics, and implemented 
solutions among others.
Search Process
First Step
Figure 1 shows the search process. In 2017, eligible studies were 
first identified from a search of PubMed with the following general 
MeSH terms strategy “DRUG OR MEDICINE AND SHORTAGE.” 
The results were subsequently filtered by period (5 years from 
May 2012 to 2017), with references filtered by tittle and abstract 
taking into account representative descriptions of countries.
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Other gray literature was retrieved from websites of the WHO, 
ministries of health and national health authorities. In addition, 
legal acts, as well as information gathered and disclosed within 
the public domain by organizations involved in pharmaceutical 
markets.
Second Step
Figure 2 shows the search process for the update implemented in 
2019. The same search strategy was used filtered by period (January 
2016 until April 2019) to help recover additional eligible studies. 
The strategy was also translated into Portuguese and Spanish to run 
a search in Lilacs, a specific database for Latin America countries.
To retrieve other potential studies, free text search terms and 
a snowball literature review was undertaken. We ran the term 
“SHORTAGE” with specific countries and continents including 
Africa, Australia, Canada, China, Costa Rica, Japan, Mexico, 
Panama and the United Kingdom.
Inclusion Criteria
This review includes studies that describe the medicines shortage 
situation within a large jurisdiction or system of care, and settings 
could be regional, national, or international.
Selection Process
Two reviewers (EV, AA) performed the screening of abstracts 
based on the tittle/abstract review. The full text of potential 
eligible studies was retrieved if one or both authors thought they 
were relevant. Disagreements were resolved by discussion and, 
when necessary, including a third author (TB) in the discussion.
Data Extraction
Data extracted from each study included the authors and year of 
publication, jurisdictional level, existence of definitions, general 
characteristics of shortages, medicines involved, description of 
information systems including four categories of frequencies of 
FIGURE 1 | Flow chart of first literature review process.
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shortages reports (high, medium, low, unspecified), potential 
and perceived causes of shortages, and possible implemented 
solutions at jurisdictional levels.
RESULTS
Description of Studies
By 2017, the literature review had identified 50 references to include 
in this scoping review, and by 2019 another 6 new references where 
identified. Of these 56 references, 9 studies had a regional broad 
focus for Europe and Latin America. We found studies with country 
description of medicines shortage for one East Asia country (China), 
7 European countries (Belgium, Finland, France, Ireland, Slovenia, 
Spain and the United Kingdom), two Latin America countries 
(Brazil and Venezuela); two North American countries (Canada and 
the United States); two Oceania countries (Australia and Fiji); and 
4 Western Asia countries (Iran, Iraq, Jordan and Israel) (Table 1).
Three of the identified articles had developed surveys 
addressed to the ministries of health, state medicines agencies and 
local health authorities of various countries from three regions to 
discuss potential ways to address medicine shortages (Bogaert 
FIGURE 2 | Flow chart of second literature review process.
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TABLE 1 | Distribution of included references by geography.
Region/country Number Ref Total by region
East Asia 1
China 1 • Yang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., et al. (2016). Current situation,determinants, and solutions 
to drug shortages in Shaanxi Province, China: a qualitative study. PLoS ONE 11: e0165183. doi: 10.1371/
journal.pone.0165183 (Yang et al., 2016)
Europe 16
Europe (broad 
focus)
8 • Bochenek T, Abilova V, Alkan A, Asanin B, Beriain I de M, Besovic Z, et al. Systemic measures and legislative 
and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western 
Asian Countries. Front Pharmacol. 2018;8(JAN). (Bochenek et al., 2018)
• Pauwels, K., Huys, I., Casteels, M., and Simoens, S. (2014). Drug shortages in European countries: a trade-
off between market attractiveness and cost containment? BMC Health Serv Res. 14:438. doi: 10.1186/1472-
6963-14-438 (Pauwels et al., 2014)
• Pauwels, K., Simoens, S., Casteels, M., and Huys, I. (2015). Insights into European drug shortages: a survey 
of hospital pharmacists. PLoS ONE 10:e0119322.doi: 10.1371/journal.pone.0119322 (Pauwels et al., 2015)
• Birgli, A. G. (2013). An Evaluation of Medicines Shortages in Europe with More In-Depth Review of These in 
France, Greece, Poland, Spain and the United Kingdom. Available online at: https://www.eaepc.org/images/
pdf/evaluation.pdf (Birgli® ag, 2013)
• Bogaert, P., Bochenek, T., Prokop, A., and Pilc, A. (2015). A qualitative approach to a better understanding 
of the problems underlying drug shortages, as viewed from Belgian, French and the European Union’s 
perspectives. PLoS ONE 10:e0125691. doi: 10.1371/journal.pone.0125691 (Bogaert et al., 2015)
• De Weerdt, E., Simoens, S., Casteels, M., and Huys, I. (2017b). Clinical, economic and policy implications of 
drug shortages in the European union. Appl. Health Econ. Health Policy 15, 441–445. doi: 10.1007/s40258-
016-0264-z. (de Weerdt et al., 2017)
• De Weerdt, E., Simoens, S., Hombroeckx, L., Casteels, M., and Huys, I. (2015b).Causes of drug 
shortages in the legal pharmaceutical framework. Regul. Toxicol.Pharmacol. 71, 251–258. doi: 10.1016/j.
yrtph.2015.01.005 (De Weerdt et al., 2015b)
• De Weerdt E, Simoens S, Casteels M, Huys I. Toward a European definition for a drug shortage: A qualitative 
study. Front Pharmacol. 2015;6(OCT):1–9. (De Weerdt et al., 2015a)
Belgium 1 • Bauters T, Claus BO, Norga K, Huys I, Simoens S, Laureys G. Chemotherapy drug shortages in paediatric 
oncology: A 14-year single-center experience in Belgium. J Oncol Pharm Pract [Internet]. 2016;22(6):766–70. 
Available from: http://opp.sagepub.com/cgi/doi/10.1177/1078155215610915 (Bauters et al., 2016)
Finland 1 • Heiskanen, K., Ahonen, R., Kanerva, R., Karttunen, P., and Timonen, J. (2017). The reasons behind medicine 
shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland. 
PLoS ONE 12:e0179479.doi: 10.1371/journal.pone.0179479. (Heiskanen et al., 2017)
France 1 • Bocquet, F., Degrassat-Théas, A., Peigné, J., and Paubel, P. (2017). The new regulatory tools of 
the 2016 Health Law to fight drug shortages in France. Health Policy 121, 471–476. doi: 10.1016/j.
healthpol.2017.03.007 (Bocquet et al., 2017)
Ireland 1 • Kavanagh J. (2017). How Pharmaceutical Supply Chains Can Be Managed to Minimise the Number of 
Medicines Shortages, Unpublished Master’s thesis, University College Dublin, Ireland. (Kavanagh, 2017)
• Vella Bonanno, P., and Gavril, F. (2011). Seven years of EU Pharmaceutical regulation in Malta. WHO Drug Inf. 
25, 341–412. (Bonnanno and Gavril, 2011)
Slovenia 1 • Pfeffer, K., and Mozolová, B. (2017). Re-export of drugs in the Slovak Republic vol. 2 – the Act [Internet]. 
Available: https://www.twobirds.com/en/news/articles/2017/uk/ils/re-export-of-drugs-in-the-slovak-republic-
vol-2-the-act (Pfeffer and Mozoľová, 2017)
Spain 1 • Servicio Vasco de Salud -Osakidetza. Desabastecimiento De Medicamentos: Un Problema Sin Resolver 
[Internet]. Vol. 23, INFORMACIÓN FARMACOTERAPÉUTICA DE LA COMARCA. Vitoria - Gasteiz; 2016. 
Available from: http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_infac_2015/es_def/
adjuntos/INFAC_Vol_23_N_7_Desabastecimientos.pdf (Servicio Vasco de Salud –Osakidetza, 2016) 
United Kingdom 2 • Costelloe, E. M., Guinane, M., Nugent, F., Halley, O., and Parsons, C. (2014). An audit of drug shortages in a 
community pharmacy practice. Ir. J. Med. Sci.435–440. doi: 10.1007/s11845-014-1139-7 (Costelloe et al., 
2015)
• Group AP. Why drug shortages occur. Drug Ther Bull [Internet]. 2015;53(3):33–6. Available from: https://dtb.
bmj.com/content/53/3/33.full (All-party Pharmacy, 2015)
Latin America 3
Latin America 
(broad focus)
1 • ISAGS. Situation of Essential Medicines at Risk of Supply Shortage with Emphasis on South American 
Countries [Internet]. Rio de Janeiro; 2017. Available from: http://isags-unasur.org/en/publicacao/situation-of-
essential-medicines-at-risk-of-supply-shortage-with-emphasis-on-south-american-countries-2/ (ISAGS, 2017)
Brazil 1 • Perini E, Rosa MB, Reis AMM, Perini E. Drug shortage: a public health problem. Cad Saude Publica 
[Internet]. 2016 Oct [cited 2017 Jul 10];32(10). Available from: http://www.scielo.br/scielo.php?script=sci_
arttext&pid=S0102-311X2016001000301&lng=en&tlng=en (Rosa et al., 2016)
Venezuela 1 • Aular de González Y. Escasez de medicamentos y su repercusión en la salud. Salus. 2014;18(2):5–6. (Aular 
de González, 2014)
(Continued)
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TABLE 1 | Continued
Region/country Number Ref Total by region
North America 29
Canada 3 • Morrison, A. (2011). Drug Supply Disruptions [Environmental Scan Issue 17]Ottawa: Canadian Agency 
for Drugs and Technologies in Health. Available online at: https://www.cadth.ca/drug-supply-disruptions 
(Morrison, 2011)
• Kaposy C. Drugs, money, and power: the Canadian drug shortage. J Bioeth Inq [Internet]. 2014 Mar [cited 
2014 May 29];11(1):85–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24357073
• Videau M, Lebel D, Bussières JF. Drug shortages in Canada: Data for 2016–2017 and perspectives on the problem. 
Ann Pharm Fr [Internet]. 2019; Available from: https://doi.org/10.1016/j.pharma.2018.11.007 (Videau et al., 2019)
United States 26 • Schweitzer, S. O. (2013). How the US Food and Drug Administration can solve the prescription drug shortage 
problem. Am. J. Public Health. 10310–14. doi: 10.2105/AJPH.2013.301239 (Schweitzer, 2013)
• Ventola, C. L. (2011). The drug shortage crisis in the United States: causes, impact, and management 
strategies. P T. 36, 740–757. (Ventola, 2011)
• Goldsack, J. C., Reilly, C., Bush, C., McElligott, S., Bristol, M. N., Motanya, U. N., et al. (2014). Impact of 
shortages of injectable oncology drugs on patient care. Am. J. Heal. Pharm. 71, 571–578. doi: 10.2146/
ajhp130569 (Goldsack et al., 2014)
• Butterfield, L., Cash, J., and Pham, K. (2015). Position statement drug shortages and implications for 
pediatric patients. J. Pediatr. Pharmacol. Ther. 20, 149–152. doi: 10.5863/1551-6776-20.2.149 (Butterfield 
et al., 2015)
• Mazer-Amirshahi, M., Goyal, M., Umar, S. A., Fox, E. R., Zocchi, M., Hawley, K.L., et al. (2017). U.S. drug 
shortages for medications used in adult critical care(2001-2016). J. Crit. Care. 41, 283–288. doi: 10.1016/j.
jcrc.2017.06.005 (Mazer-Amirshahi et al., 2017)
• McLaughlin,M.M., and Skoglund, E.W. (2015). Drug shortages and patient safety. J. Infus. Nurs. 38, 205–208. 
doi: 10.1097/NAN.0000000000000101
• McLaughlin, M., Kotis, D., Thomson, K., Harrison, M., Fennessy, G., Postelnick, M., et al. (2013). Effects 
on patient care caused by drug shortages: a survey. J. Manag. Care Pharm. 19, 783–788. doi: 10.18553/
jmcp.2013.19.9.783
• McKeever AE, Bloch JR, Bratic A. Drug shortages and the burden of access to care: A critical issue affecting 
patients with cancer. Clin J Oncol Nurs. 2013; (McKeever et al., 2013)
• Alevizakos M, Detsis M, Grigoras CA, Machan JT, Mylonakis E. The Impact of Shortages on Medication 
Prices: Implications for Shortage Prevention. Drugs. 2016;76(16):1551–8 (Alevizakos et al., 2016)
• Griffith MM, Gross AE, Sutton SH, Bolon MK, Esterly JS, Patel JA, et al. The impact of anti-infective drug 
shortages on hospitals in the United States: Trends and causes. Clin Infect Dis. 2012;54(5):684–91. (Griffith 
et al., 2012)
• Steers WD. Falling short: Causes and Implications of Drug Shortages in the United States. J Urol [Internet]. 
2014;192(5):1315–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25218647 (Steers, 2014)
• Gabrielli A, Layon NT, Bones HL, Layon AJ. The Tragedy of the Commons - Drug Shortages and Our Patients’ 
Health. Am J Med [Internet]. 2016;129(12):1237–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/
S0002934316310130%0A http://www.ncbi.nlm.nih.gov/pubmed/28029357 (Gabrielli et al., 2016)
• Rinaldi F, de Denus S, Nguyen A, Nattel S, Bussières J-F. Drug Shortages: Patients and Health Care Providers 
Are All Drawing the Short Straw. Can J Cardiol [Internet]. 2016; Available from: http://linkinghub.elsevier.com/
retrieve/pii/S0828282X1630842X%0A http://www.ncbi.nlm.nih.gov/pubmed/27923583 (Rinaldi et al., 2017)
• Parsons HM, Schmidt S, Karnad AB, Liang Y, Pugh MJ, Fox ER, et al. Association Between the Number 
of Suppliers for Critical Antineoplastics and Drug Shortages: Implications for Future Drug Shortages and 
Treatment. J Oncol Pract [Internet]. 2016;12(3):249–50. Available from: http://jop.ascopubs.org/cgi/
doi/10.1200/JOP.2015.007237
• Chen SI, Fox ER, Kennedy Hall M, Ross JS, Bucholz EM, Krumholz HM, et al. Despite federal legislation, 
shortages of drugs used in acute care settings remain persistent and prolonged. Health Aff. 2016;35(5):798–
804. (Chen et al., 2016)
• Fox ER, Tyler LS. Potential Association between Drug Shortages and High-Cost Medications. 
Pharmacotherapy [Internet]. 2016; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27891635 (Fox and 
Tyler, 2017)
• Warkentin J, Flood J, Kanouse J, Shah N, Cronin A. Impact of a Shortage of First-Line Antituberculosis 
Medication on Tuberculosis Control — United States, 2012–2013. Morb Mortal Wkly Rep - CD [Internet]. 
2013;62(20):396–400. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23698603
• Jagsi R., Spence R., Rathmell W.K., Bradbury A., Peppercorn J., et al. Ethical considerations for the clinical 
oncologist in an era of oncology drug shortages. Oncologist. 2014;19(2):186–92. (Jagsi et al., 2014)
• Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, et al. Impact of oncology drug shortages on 
patient therapy: unplanned treatment changes. J Oncol Pract. 2013;9(4):122–8. (Becker et al., 2013)
• Gupta DK, Huang S-M. Drug Shortages in the United States: A Critical Evaluation of Root Causes and the 
Need for Action. Clin Pharmacol Ther [Internet]. 2013;93(2):133–5. Available from: http://www.ncbi.nlm.nih.
gov/pubmed/23337520 (Gupta and Huang, 2013)
(Continued)
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et al., 2015; ISAGS, 2017; Bochenek et al., 2018). One study 
described the literature review in terms of the characteristics of 
shortages and country definitions of shortages (De Weerdt et al., 
2015a). Another regional study described the shortage situation 
from the perspective of hospital pharmacists and prescribers 
(Pauwels et al., 2015).
The United States (US) is the country with more publications 
in the field (26 references) than many other countries. Many of 
these publications describe the professionals’ perspective of the 
situation at the health care jurisdictional level (Morrison, 2011; 
Golembiewski, 2012; Griffith et al., 2012; Becker et al., 2013; 
McKeever et al., 2013; McLaughlin et al., 2013; Bible et al., 2014; 
Goldsack et al., 2014; Butterfield et al., 2015; Caulder et al., 2015; 
McLaughlin and Skoglund, 2015; Gabrielli et al., 2016; Parsons 
et al., 2016; Setayesh and Mackey, 2016; Bocquet et al., 2017; Fox 
and Tyler, 2017; Mazer-Amirshahi et al., 2017; Rinaldi et al., 2017; 
Schwartzberg et al., 2017). Another study performed a comparison 
of medicines shortages between two hospital settings, one from 
Arabia Saudi and the other from the US (Alsheikh et al., 2016).
Contexts and Reasons of Medicines 
Shortage
The description of the shortage situations may be associated with 
4 principal causes or determinants, namely: market, supply chain 
management, manufacturing, and political issues (Table 2).
TABLE 1 | Continued
Region/country Number Ref Total by region
• Caulder C, Mehta B, Bookstaver P, Sims L, Stevenson B, South Carolina Society of Health-Sy. Impact of 
Drug Shortages on Health System Pharmacies in the Southeastern United States. Hosp Pharm [Internet]. 
2015;50(4):279–86. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589883/pdf/hpj-50-279.
pdf (Caulder et al., 2015)
• Golembiewski J. Drug shortages in the perioperative setting: causes, impact, and strategies. J Perianesth 
Nurs [Internet]. 2012 Aug [cited 2013 Mar 7];27(4):286–92. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/22828028 (Golembiewski, 2012)
• Daley M, Lat I, Kane-Gill S. Applicability of Guideline Recommendations Challenged in the Setting of Drug 
Shortages. Crit Care Med [Internet]. 2013;41(7):e142–3. Available from: http://content.wkhealth.com/
linkback/openurl?sid=WKPTLP:landingpage&an=00003246-201307000-00058
• McLaughlin M, Kotis D, Thomson K, Harrison M, Fennessy G, Postelnick M, et al. Effects on Patient Care 
Caused by Drug Shortages: A Survey. J Manag Care Pharm [Internet]. 2013;19(9):783–8. Available from: 
http://www.jmcp.org/doi/10.18553/jmcp.2013.19.9.783 (McLaughlin et al., 2013)
• Administra- D, Act I, Hoffman RS. Antidote shortages in the United States: impact and response. Clin 
Toxicol (Phila) [Internet]. 2014;52(3):157–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24397753 
(American College of Medical Toxicology, American Academy of Clinical Toxicology, 2015)
• Bible JR, Evans DC, Payne B, Mostafavifar L. Impact of Drug Shortages on Patients Receiving Parenteral 
Nutrition After Laparotomy. J Parenter Enter Nutr [Internet]. 2014;38(2_suppl):65S–71S. Available from: http://
journals.sagepub.com/doi/10.1177/0148607114550317
Oceania 2
Australia 1 • The Society of Hospital Pharmacists of Australian, SHPA. Medicine shortages in Australia. A snapshot of 
shortages in australian hospitals. Victoria; 2017. (The Society of Hospital Pharmacists of Australian, SHPA, 
2017)
Fiji 1 • Walker, J., Chaar, B. B., Vera, N., Pillai, A. S., Lim, J. S., Bero, L., et al. (2017). Medicine shortages in Fiji: a 
qualitative exploration of stakeholders’ views. PLoS ONE 12:e0178429. doi: 10.1371/journal.pone.0178429 
(Walker et al., 2017)
Western Asia 4
Iran 1 • Setayesh S, Mackey TK. Addressing the impact of economic sanctions on Iranian drug shortages in the joint 
comprehensive plan of action: promoting access to medicines and health diplomacy. Global Health [Internet]. 
2016;12(1):31. Available from: http://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-
016-0168-6 (Setayesh and Mackey, 2016)
Iraq 1 • Cousins S. Iraq: staff and medicine shortages are major challenges. Lancet [Internet]. 2014;384(9947):943–4. 
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673614616159 (Cousins, 2014)
Jordan 1 • Awad, H., Al-Zu’bi, Z.M. F., and Abdallah, A. B. (2016). A quantitative analysis of the causes of drug 
shortages in Jordan: a supply chain perspective. Int. Bus. Res.9:53. doi: 10.5539/ibr.v9n6p53 (Awad et al., 
2016)
Israel 1 • Schwartzberg E, Ainbinder D, Vishkauzan A, Gamzu R. Drug shortages in Israel: regulatory perspectives, 
challenges and solutions. Isr J Health Policy Res [Internet]. 2017;6(1):17. Available from: http://
ijhpr.biomedcentral.com/articles/10.1186/s13584-017-0140-9%0A http://www.ncbi.nlm.nih.gov/
pubmed/28392910%0A http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5376685 
(Schwartzberg et al., 2017)
Cross settings 
comparisons 
between countries
1
The United States 
and Arabia Saudi – 
Hospital Setting
1 • Alsheikh, M., Seoane-Vazquez, E., Rittenhouse, B., Fox, E. R., and Fanikos, J. (2016). A comparison of 
drug shortages in the Hospital Setting in the United States and Saudi Arabia: an exploratory analysis. Hosp. 
Pharm. 51,370–375. doi: 10.1310/hpj5105-370 (Alsheikh et al., 2016)
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Some authors have concluded that these categories are 
interrelated and have one aspect in common, that is, many cases 
are related to the availability of safe and effective medicines 
with low profitability or with low sales making them non-viable 
commercially (McKeever et al., 2013; Alevizakos et al., 2016; 
Schwartzberg et al., 2017).
In South American countries, medicine shortages generally 
occur with mature products without suppliers in the market due 
to lack of market viability, and correspond mostly to parenteral 
medicines with low profitability (ISAGS, 2017).
Some countries issue alerts about medicines that are simply 
not available on the market in their country even if there is 
enough money to pay for them within their health care systems 
(Bochenek et al., 2018).
Finally, Bochenek et al. (2018) addressed an increasing 
amount of evidence where medicines were unavailable in 
countries even if the products complied with current regulations 
and were financed within the health care system. As a result, 
these situations show that ethical and political issues could 
be affecting the timely availability of first-line therapeutic 
alternatives. These situations threaten the ability of clinicians 
and governments to fulfill their moral obligations to patients 
and society to provide benefit to patients, minimize harm, and 
promote equity.
Published studies in hospitals allow a better follow up of the 
health consequences of medicine shortages (Pauwels et al., 2015; 
de Weerdt et al., 2017); which is more difficult in ambulatory 
care (Golembiewski, 2012; Becker et al., 2013; Goldsack et al., 
2014; Jagsi et al., 2014; Chen et al., 2016). This scoping review 
identified a number of published articles describing inpatient 
challenges regarding medicine shortages in the US (Morrison, 
2011; Golembiewski, 2012; Griffith et al., 2012; Becker et al., 2013; 
McKeever et al., 2013; McLaughlin et al., 2013; Bible et al., 
2014; Goldsack et al., 2014; Butterfield et al., 2015; Caulder et al., 
2015; McLaughlin and Skoglund, 2015; Gabrielli et al., 2016; 
Parsons et al., 2016; Setayesh and Mackey, 2016; Bocquet et al., 
2017; Fox and Tyler, 2017; Mazer-Amirshahi et al., 2017; Rinaldi 
et al., 2017; Schwartzberg et al., 2017).
Medicines Involved
The characterization of supply shortages, their frequency, and the 
main groups of medicines affected among countries and regions 
are described in Table 3. The same characterization though is not 
made for the impact of shortages on patients’ health and health 
care systems. Descriptions in this respect generally correspond 
to descriptions of cases regarding either the impact of shortages 
on health conditions or medical specialties, or limitations in 
obtaining data and estimates made from surveys.
The shortage of essential medicines, including the active 
ingredients mostly used in injectable chemotherapy medicines, 
antibiotics, and anesthesia, is causing growing concern across 
regions including Europe, North America, Asia, and South 
America. However, the problem is much broader, affecting other 
classes of medicines - mainly parenteral medicines (Becker et al., 
2013; Gulbis et al., 2013; Gupta and Huang, 2013; Jagsi et al., 
2014; Caulder et al., 2015; De Weerdt et al., 2015b; De Weerdt 
et al., 2017; Schwartzberg et al., 2017) including anesthetics, 
nutrition and electrolyte solutions, enzyme replacement 
medicines, radiopharmaceuticals and antibiotics. The shortage 
of medicines has also been observed and documented for instance 
in Australia, Canada, China and Israel (Gray and Manasse, 2012; 
Kaposy, 2014; Schwartzberg et al., 2017). Most of the published 
evidence from countries of South America shows that shortages 
can occur even with essential medicines and especially injectable 
forms (ISAGS, 2017) (see Figure 3).
The groups of medicines, which were most frequently reported 
to be in shortage, were the cardiovascular medicines in Canada 
and Belgium; nervous system medicines in Australia, China, and 
Israel; and anti-infective medicines for most of the countries in 
South America (Bogaert et al., 2015; Yang et al., 2016; ISAGS, 
2017; Schwartzberg et al., 2017; Videau et al., 2019).
Brazil has reported the national shortage of penicillins (first-
line treatment) as a result of the lack of specific raw materials 
for their production in the international market. This episode 
TABLE 2 | Most frequent reasons for medicine shortages.
Category Cause
Market Increase in sales (McKeever et al., 2013; Ordre National 
des Pharmaciens, 2015)
Price-related aspects (McKeever et al., 2013; Ordre 
National des Pharmaciens, 2015; Alevizakos et al., 2016; 
Yang et al., 2016)
Voluntary withdrawal (Griffith et al., 2012; Steers, 2014; 
Chen et al., 2016; Yang et al., 2016; Rinaldi et al., 2017)
Unexpected increases and unexpected changes in 
clinical practice (Griffith et al., 2012; Yang et al., 2016)
Parallel or gray markets (Yang et al., 2016)
Loss of market interest (Videau et al., 2019)
Relocation of production facilities (Videau et al., 2019)
Speculation in international markets (Videau et al., 2019)
Mergers of manufacturers and joint purchasing group 
(Videau et al., 2019)
Supply chain 
management
Structure of the network or supply chain in the country 
(Schwartzberg et al., 2017)
Supply of raw materials and excipients (Griffith et al., 
2012; Ordre National des Pharmaciens, 2015; Chen 
et al., 2016; Gabrielli et al., 2016; Parsons et al., 2016; 
Bocquet et al., 2017; Rinaldi et al., 2017; Schwartzberg 
et al., 2017)
Manufacturing 
process
Quality concerns (Griffith et al., 2012; Gabrielli et al., 
2016; Bocquet et al., 2017; De Weerdt et al., 2017; 
Rinaldi et al., 2017; Schwartzberg et al., 2017)
Changes in the product formulation (Yang et al., 2016; 
Rinaldi et al., 2017)
Industrial development capacities (Steers, 2014; Gabrielli 
et al., 2016; Yang et al., 2016; Fox and Tyler, 2017)
Production problems (Videau et al., 2019)
Political and ethical 
issues
Regulatory problems (McKeever et al., 2013; Chen et al., 
2016; Gabrielli et al., 2016; Parsons et al., 2016; Yang 
et al., 2016; Bocquet et al., 2017; Schwartzberg et al., 
2017).
Public policy (Cousins, 2014; Setayesh and Mackey, 
2016; French Parliament).
Social conflicts (Setayesh and Mackey, 2016; Bochenek 
et al., 2018).
Enhancement of the legal and normative frameworks 
applicable to the manufacture of medicines (Videau 
et al., 2019)
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was described because of the increased incidence of syphilis, 
including also congenital syphilis, during the last 5 years and the 
concern this causes (see Figure 4). The alternative second-line 
antibiotics to treat acquired syphilis and the partners of pregnant 
women in Brazil, i.e., doxycycline and ceftriaxone, have doses of 
between 8 and 15 days, and there are concerns with adherence in 
practice (Lazarini and Barbosa, 2017).
In France (Bocquet et al., 2017), supply shortages with 
71 types of medicine were identified. According to the ATC 
classification (Norwegian Institute of Public Nealth, 2018), the 
most prevalent medicine were antibiotics, oncological medicines, 
antidepressants, antipsychotics, tuberculosis medicines, vaccines, 
and immunoglobulins.
In Iran, at least 73 cases of medicine shortages were identified, 
among which 44% were essential. Potentially, they impacted on 
successful management of disease areas including HIV, epilepsy, 
hemophilia, thalassemia, and patients undergoing organ 
transplants (Setayesh and Mackey, 2016).
FIGURE 3 | Principal medicine groups experiencing shortages among South American countries.
TABLE 3 | Description of medicines classes with shortages in the selected countries.
Region/country* Nervous system Cardiovascular 
system
Anti-infectives 
systemic use
Cancer Genitourinary 
system and sex 
hormones
Alimentary track 
and metabolism
South America 2017 17% 9% 21% 10% 7% Non available
Belgium 2009–2013 23% 21% 11% 9% Non available 8%
Israel 2013–2015 21% 15% 16% Non available 8% 7%
US 2013–2017 18% 11% Non available 9% Non available Non available
Canada 
(Videau et al., 2019)
31.8% 21.9% 8.5% 5.1% Non available 0.1%
Australia 
(The Society of 
Hospital Pharmacists 
of Australian, SHPA, 
2017)
12% 
(Anaesthetics)
9% (Neurology)
10% 20% 9.5% 10% Non available
China (Yang et al., 
2016)
13% 6% 6% 5.7% 11% 9%
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Definitions
National Definitions
Table 4 contains definitions adopted by countries, considering 
attributes with the formulation and agreement of potential 
definitions.
One of the most important findings of this scoping review is 
that consulted sources, literature and institutional websites, have 
identified a considerable number of countries that are introducing 
legislative actions to cope the medicines shortages and had 
included formal definitions or related terms of medicine shortages.
Recently, Bochenek et al (2018) identified four countries in 
Europe with specific definitions, and ISAGS in 2017 (ISAGS, 
2017) described three definitions for Latin American countries. 
This scoping review found progress in both regions, i.e., eight 
European countries and seven Latin America now have national 
medicines shortage definitions. In addition, by using free terms 
in the search strategies, we found definitions for one more region, 
North America (Canada and the United States), and for one 
country, Australia (Table 4). There are two primary sources of 
definitions: one from health authority agency websites (Argentina, 
Australia, Brazil, Colombia, Spain, US, Uruguay, Norway), and the 
other is the published literature for countries including Belgium, 
Canada, France, Greece, Hungary, and Italy (Bogaert et al., 2015; 
Bocquet et al., 2017; Bochenek et al., 2018; Videau et al., 2019).
Few countries have currently established a specific definition that 
includes the term “shortages” alone or in combination with the terms 
“medicines” or “drugs.” These include Belgium, Canada, Colombia, 
France, Hungary, Greece, Italy, Spain, and the US (Table 4).
Some countries have used logistics and market related 
terms, including Uruguay (declaration of interruption of sale 
or interruption of marketing), Argentina (medicines lacking), 
Croatia (disturbance on the medicines’ market), Norway 
(temporary disruption of a medicine’s marketing), Brazil, 
which uses the term “discontinuation” complemented with 
a term related to the temporality (definitive or unplanned or 
temporary), Italy (short supply), and Peru, which uses three 
terms “supply shortage,” “unavailable pharmaceutical products,” 
and “pharmaceutical product with limited supply” (Table 4).
The United States Food and Drug Administration (US FDA) 
has focused more on aspects related to scarcity and established a 
definition: “a period when the demand or projected demand for a 
medically necessary drug in the United States exceeds its supply” 
(CDER C for DE and research, 2018).
Bolivia, Chile, Croatia, Ecuador, Greece, Hungary, Norway, and 
Venezuela currently do not have an official definition of medicine 
shortage. These countries consider terms associated with medicine 
shortages but currently do not define the term medicine shortages 
(Bochenek et al., 2018). Finally, Venezuela differentiates scarcity as 
the situation in which there is insufficient quantity of a medicine 
to meet current demand and a supply shortage when the product is 
just not available (Ministerio de Salud Venezuela, 2017).
Country Approaches
A new website at the European Medicines Agency (EMA) includes 
information about national legislation and local report mechanisms 
for 24 of the 30 European countries1. In South America, Brazil, 
Argentina, and Uruguay have regulations that make the reporting 
of situations that could potentially lead to shortages mandatory. 
EMA also have a regulation to report these cases.
Two qualitative studies have documented countries’ legislation 
and report mechanisms for three regions: Europe, Western Asia, and 
South America (ISAGS, 2017; Bochenek et al., 2018). As mentioned, 
this scoping review described one new region, North America 
(Center for Drug Evaluation and research C, 2018; Videau et al., 
1 European Medicines Agency. Medicine shortages. https://www.ema.europa.eu/
en/human-regulatory/post-authorisation/medicine-shortages
FIGURE 4 | Detection rate of syphilis and congenital syphilis in Brazil. Source: Brazil Ministry of Health.
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2019). In addition, it was possible to include information from 12 new 
countries: Australia, Bulgaria, Canada, Czech Republic, Denmark, 
Finland, Germany, Iceland, Romania, Sweden, United Kingdom 
(UK), and the US (All-party Pharmacy, 2015; Schwartzberg et al., 
2017; The Society of Hospital Pharmacists of Australian, SHPA, 
2017; CDER C for DE and research, 2018; Videau et al., 2019).
Information Systems and Vigilance
Countries are taking actions regarding legislation and reporting 
systems in public websites (Table 5). Most of them are at the 
National Regulatory Agency level (28 countries), whereas others 
are at the Ministries of Health or National Health System level, 
including Colombia, Israel, Malta, Poland, Spain, Switzerland, 
TABLE 4 | Countries definitions.
Country Terms/concepts Definition
Argentina Medicines lacking “known circumstances or facts that could jeopardize the supply of products and cause their temporary or 
definitive discontinuity in the market”1
Australia Shortage of a medicine “There is a shortage of a medicine in Australia at a particular time if, at any time in the 6 months after that 
particular time, the supply of that medicine in Australia will not, or will not be likely to, meet the demand for the 
medicine for all of the patients in Australia who take, or who may need to take, the medicine”2 (The Society of 
Hospital Pharmacists of Australian, SHPA, 2017)
Belgium Unavailability of medicines on the 
Belgian market
“A drug is unavailable when enterprises that are responsible for the marketing of the drug are unable to 
deliver that drug for an uninterrupted period of four consecutive days to the community pharmacies, hospital 
pharmacies or wholesalers in Belgium.” (De Weerdt et al., 2015a)
Brazil “Temporary discontinuation”
“Definitive discontinuation”
“Unplanned discontinuation of 
the manufacture or importation of 
medicines”
of the manufacture or importation of medicines means that the license holder does not intend to cancel or does 
not intend to require the renewal of the registration of the product.
of a product, in its turn, happens when the license holder intends to cancel or not to request the renewal of the 
registration of the product.
Are those cases where quality, efficacy or safety properties of medicines are affected and may lead to a supply 
shortage in the market. (ISAGS, 2017)
Colombia Medicines shortage A situation which there is not enough supply to satisfy the demand of any medicine approved and marketed in 
at the country. (INVIMA, 2018)
Canada Drug shortage A situation in which an authorization holder for a drug is unable to meet the demand for the drug. Drug 
shortages can include temporary or permanent discontinuances in the production and supply of a drug (Videau 
et al., 2019)
Croatia Disturbance on the medicines’ 
market
Not specific.
France Drug shortage A drug shortage is defined by law in France as an inability for a community pharmacy or a hospital pharmacy to 
deliver a drug within 72 h (Ministre des affaires sociales, Ministre de la santè, 2012). Additionally, drug shortages 
in France have been classified formally into two separate contexts of either stock or supply problems. A 
stock-related shortage is defined as the lack of possibility to manufacture a medicine, whereas a supply-related 
shortage is defined as a problem in the distribution chain that makes the supply of a medicine impossible, even 
if enough of the medicine has been manufactured (De Weerdt et al., 2015a).
Greece Actual shortages
Temporary interruptions in supply
“Pertains to the lack of capability to fulfill the demand and the non-availability of a drug in the whole health care 
system, without the possibility to obtain that medicine from any source.”
“It refers to situations when drugs are not commercially available,”
mainly for commercial reasons, for a limited time duration (Bochenek et al., 2018).
Hungary “Drug shortage” As a term is reported to be widely used in the legislation, to report in case they are not able to supply, but 
without any association with a concrete formal definition (Bochenek et al., 2018).
Italy Short supply The Italian Medicines Agency (AIFA) defines medicines in short supply as: “Medicines which are not available 
or not to be found in the whole Italian market, because the marketing authorization holder (MAH) is unable to 
guarantee the correct and regular supply to meet patients’ needs.” (Bochenek et al., 2018).
Norway Temporary disruption of a
medicine’s marketing
It is de facto considered to be a shortage as soon as it lasted for at least 2 weeks (Bochenek et al., 2018).
Peru “Supply shortage”
Unavailable Pharmaceutical 
Products
Pharmaceutical product with 
limited supply
Considered as an operational definition in the management of drug availability indicators employed by the public 
bodies within the Ministry of Health and Regional Governments.
Essential pharmaceutical products not supplied in the national market.
Product with limited provision in the pharmaceutical market, which could generate access problems (availability 
and affordability) for the population
Spain Supply problem The Spanish Agency for Medicines and Health Products (Spanish acronym: AEMPS), being part of the Spanish 
Ministry of Health Care, defined the “supply problem” as a situation in which the number of available units of a 
drug in the pharmaceutical trade channel is below the level of national or local consumption needs, being often 
due to problems in the manufacturing or distribution of a drug
United States Medicines shortages “A period when the demand or projected demand for a medically necessary drug in the United States exceeds 
its supply” (Center for Drug Evaluation and research 2018).
Uruguay Declaration of interruption of sale
Interruption of marketing
Interruptions lasting 30 days or more.
Due to exceptional interruptions by the manufacturer lasting less than 30 days, which must be communicated 
to and validated by the Department of Medicines. (ISAGS, 2017)
1 Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. https://www.argentina.gob.ar/anmat
2 The Therapeutic Goods Administration. Medicine Shortages Information Initiative Available from: https://apps.tga.gov.au/prod/MSI/search#furtherinformation
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TABLE 5 | Frequency of update on the publicly available databases to report medicines shortages.
Frequency 
of updating
Country Organization in charge of 
database
Access Frequency of update Mandatory 
Reporting
High Australia Therapeutics Goods 
Administration
https://apps.tga.gov.au/prod/MSI/search Daily Yes
Belgium Federal Agency of Medicines 
and Health Products
https://banquededonneesmedicaments.fagg-
afmps.be/#/query/supply-problem-history/human
Daily (this is nominal 
frequency, which may 
be different)
Yes
Canada Bell Canada under contract 
with Health Canada
www.drugshortagescanada.ca/ Daily Yes
Czech 
Republic
State Institute for drug control http://www.sukl.eu/dodavky-leciv-se-zamerenim-
na-lecive -latky
Daily Yes
Latvia State Agency of Medicines 
(SAMLV)
https://www.zva.gov.lv//?id=781&lang=&top=33
4&sa=673
Daily Yes
Portugal [1] Portugal ANF - National 
Association of Pharmacies 
(ANF - Associação Nacional 
de Farmécias)
https://www.anfonline.pt/ Daily Yes
Sweden Swedish medical products 
agency
https://lakemedelsverket.se/OVRIGA-SIDOR/
Restnoteringar/
As soon as posible Yes
US American Society of Health 
Systems Pharmacist - ASHP
https://www.ashp.org/drug-shortages/
current-shortages
Daily Not
Medium Austria Austrian Medicines and 
Medical Devices Agency 
(AGES MEA)
www.basg.gv.at/news-center/news/news-detail/
article/uebersichtsliste-vertriebseinschraenkungen 
-986/
Weekly
Hungary National Institute of Pharmacy 
and Nutrition
https://www.ogyei.gov.hu/temporary_discontinuation_
of_ sale_/ 
Weekly Yes
Italy Italian Medicines Agency 
(AIFA—Agenzia Italiana del 
ármaco)
http://www.aifa.gov.it/content/carenze-e-
indisponibilt%C3 %A0
Weekly Yes
Malta [1] Ministry for Health (CPSU—
Central Procurement and 
Supplies Unit)
https://health.gov.mt/en/cpsu/Pages/POYC-OOS.
aspx
Weekly Yes
Norway Norwegian Medicines Agency https://legemiddelverket.no/legemiddelmangel/
legemiddelmangel-og-avregistreringer-2017-rad-
til-apotek-og-helsepersonell 
Weekly Yes
Slovakia The State Institute for Drug 
Control (SUKL)
http://www.sukl.sk/en/inspection/
post-authorization-quality-control/
export-of-medicinal-products/
list-of-medicinal-products-for-which-
they-were-issued-decisions-not-to-allow-the-
export-from-slovak-republic?page_id=4006
Weekly Yes
Spain [2] Center for Information on 
Medicines Supply (in Spanish: 
Centro de Información 
sobre el Suministro de 
Medicamentos; CISMED)
http://www.portalfarma.com/Profesionales/
consejoinforma/Paginas/Infarma-2016-CISMED.
aspx
Weekly Yes
Switzerland [1] Federal Office of Public Health https://www.bag.admin.ch/bag/de/home/
themen/mensch-gesundheit/biomedizin-
forschung/heilmittel/sicherheit-in-der-
medikamentenversorgung.html?_organization= 
317
Weekly Yes
Switzerland [2] Federal Office for national 
economic supply (FONES)
https://www.bwl.admin.ch/bwl/de/home.html Weekly Yes
Switzerland [3] Swissmedic (Swiss Agency for 
Therapeutic Products)
https://www.swissmedic.ch/marktueberwachung/ 
00135/00136/00140/00142/index.html?lang=de
Weekly Yes
Switzerland [4] Martinelli Consulting 
Switzerland
www.drugshortage.ch Weekly Not applicable 
(private and 
voluntary but 
highly effective 
initiative)
(Continued)
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TABLE 5 | Continued
Frequency 
of updating
Country Organization in charge of 
database
Access Frequency of update Mandatory 
Reporting
Turkey Turkish Medicines and Medical 
Devices Agency: TMMDA (in 
Turkish: Türkiye Ilaç Ve Tibbi 
Cihaz Kurumu; TİTCK)
http://www.titck.gov.tr/ Weekly Yes
Low Argentina National Administration of 
Medicines, Food and Medical 
Technology (ANMAT)
https://www.argentina.gob.ar/faltante-de- 
medicamentos
Twice a month Yes
Croatia Croatian Health Insurance 
Fund
http://www.hzzo.hr/zdravstveni-sustav-rh/
trazilica-za-lijekove-s-vazecih-lista/ 
Monthly Yes
France [1] French Agency for Medicines 
Safety (ANSM – Agence 
Nationale pour la Sécurité du 
Medicament)
http://ansm.sante.fr/Mediatheque/Publications/
Information-in-English
Yearly Yes
France [2] National Council of the 
College of Pharmacists 
(Conseil national de l’ordre 
national des pharmaciens –  
CNOP)
http://www.ordre.pharmacien.fr/Le-Dossier-
Pharmaceutique/Ruptures-d-approvisionnement- 
et-DP-Ruptures
Monthly Yes
Lithuania State Medicines Control 
Agency (SMCA)
www.vvkt.lt Biweekly Unspecified
Greece National Organization for 
Medicines (EOF)
http://www.eof.gr/web/guest/eparkeia Monthly (this is usual 
frequency)
Yes
Ireland [1] Irish Pharmaceutical Union 
(IPU)
https://ipu.ie/home/ipu-product-file/
medicine-shortages/
Minimum monthly, but 
on demand based 
on completion of 
medicines shortages 
notification form
Yes
Poland Ministry of Health http://www.bip.mz.gov.pl/legislacja/akty-prawne/
obwieszczenie-ministra-zdrowia-z-dnia-10-
stycznia-2017-r-w-sprawie-wykazu-produktow-
leczniczych-srodkow-spozywczych-specjalnego-
przeznaczenia-zywieniowego-oraz-wyrobow-
medycznych-zagrozonych-brakiem/
At least bimonthly Yes
Unspecified Brazil National Health Surveillance 
Agency (ANVISA)
http://portal.anvisa.gov.br/descontinuacao-de- 
medicamentos
As necessary (after 
every notification by 
MAH
Yes
Bulgary Bulgarian Drug Agency http://www.bda.bg/bg/ As requiered Not know
Colombia [1]
(may 2018 
until now)
National Institute of Food 
and Medicines Surveillance 
(INVIMA)
https://www.invima.gov.co/desabastecimiento-de- 
medicamentos
As required Yes
Colombia [2]
(2012 until 
april 2018)
Ministry of Health https://www.minsalud.gov.co/salud/MT/Paginas/
desabastecimiento.aspx
As required Yes
Denmark Danish Medicines Agency https://laegemiddelstyrelsen.dk/da/
godkendelse/kontrol-og-inspektion/
alvorlige-forsyningsvanskeligheder/#
As required Yes
Estonia Estonian State Agency of 
Medicines
http://www.ravimiamet.ee/ulevaatlik-tabel-
humaanravimite -tarneraskustest
As necessary (after 
every notification by 
MAH)
Yes
Finland The Finnish Medicines Agency 
- Fimea
https://www.fimea.fi/tietoa_fimeasta/ajankohtaista/
saatavuushairiotiedotteet
As required Yes
Germany Instituto Federal de 
Medicamentos y Dispositivos 
Médicos
https://www.bfarm.de/DE/BfArM/_node.html As required Yesit
Israel Ministry of Health www.health.gov.il According to the need Yes
Ireland [1] UniPhar www.uniphar.ie As required Yes
Kosovo Kosovo Medicines Agency www.akppm.com – No
Malta [1] Ministry for Health (CPSU – 
Central Procurement and 
Supplies Unit)
https://health.gov.mt/en/cpsu/Pages/Items-
Problematic-To-Source.aspx
As required Yes
(Continued)
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UK, and Uruguay). Five countries were documented by Bochenek 
et al. in 2018 (Gulbis et al., 2013; Bochenek et al., 2018) where 
pharmacist professional organizations and other stakeholders 
are involved in medicines shortages reports. Finally, Canada has 
a website operated by a telecommunication company (Table 5).
Some of the main features of these systems include the 
frequency of updates, the obligation of pharmaceutical 
companies or marketing authorization holders to notify key 
stakeholder groups, and public institutions in charge of the 
database. To enhance our understanding of the characteristics of 
databases on medicine shortages in selected countries of Europe, 
Western Asia, North America, and Latin America, all databases 
have been divided into four groups, depending on frequency of 
their updating: high (daily), medium (weekly), low (less often 
than weekly), and unspecified (Table 5).
Most of the countries have only a national reporting system, 
where the Ministry of Health or the National Regulatory 
Agency manage the database and request mandatory reports. 
However, other countries have more than one system involved 
in the gathering of information, such as professional associations 
in France, Ireland, Malta, Portugal, Spain, and Switzerland 
(Bochenek et al., 2018). Finally, 12 of 40 countries have not 
reported databases on medicine shortage, six from Europe 
(Albania, Cyprus, Lichtenstein, Montenegro, Netherlands, 
Serbia), seven from South America (Guyana, Suriname, Ecuador, 
Bolivia, Paraguay, Peru, Venezuela), and Azerbaijan from Western 
Asia. None of the databases reported affected health conditions, 
or the possible impact caused by the reported episode.
Although all analyzed European countries have mandatory 
reporting systems, this scoping review revealed information 
systems with high frequency of shortages reports in countries, 
such as Australia, Canada, and the US. Countries of Latin 
America and Europe have low or unspecified update frequency 
of their medicines shortages websites on their (Table 5).
Networks and Initiatives
In 2014, the South American Council for Health from UNASUR 
issued a declaration on “Access to medicines and problems of 
medicines shortage,” which stated that medicines shortage is a 
global and regional problem that manifests itself in diverse and 
changing ways, with various effects since there is insufficient 
information to determine the magnitude and features of the 
problem (ISAGS, 2017).
During 2016, several South American countries proposed to 
document the shortages situation of essential medicines in the 
region and to formulate strategies as part of the South American 
Institute of Government in Health (ISAGS UNASUR) actions 
for 2017. ISAGS UNASUR, together with the Andean Health 
Organization (Hipólito Unanue Agreement), undertook a study 
which described the situation in the member countries of the 
Andean and South American regions (ISAGS, 2017). An analysis 
of the medicines shortage situation of essential medicines was 
developed through the collection of information on decisions 
related to the problem, types of medicines identified by each 
country, identified causes, protocols of approach, solutions 
implemented, management and impact indicators, as well as 
limitations and experiences both at the country and regional 
levels that may be relevant to helping overcome the problem.
In 2016, the research collaboration initiative funded by the 
European Union was started. It is named COST CA15105—
European Medicines Shortages Research Network—addressing 
supply problems to patients (Medicines Shortages) and it 
aims to stimulate and develop scientific research, as well as to 
propose solutions by end of 2020 (COST, 2015; COST, 2018). 
The COST CA15105 network encourages systematic sharing 
of information and research about shortages of medicines and 
nutritional products. It also aims to respond to the diverse 
interests of clinical and financial parties and patients’ quality of 
life, to achieve analytical clarity on the causes of shortages, to 
TABLE 5 | Continued
Frequency 
of updating
Country Organization in charge of 
database
Access Frequency of update Mandatory 
Reporting
Republic 
of Srpska, 
Bosnia and 
Herzegovina
The Agency for Medicinal 
Products and Medical Devices 
of Bosnia and Herzegovina 
(ALMBIH)
http://www.almbih.gov.ba/vijesti/ As soon as the ALMBIH 
is informed by the MAH 
about shortage of a 
given medicine
Yes
Romania National Agency for Medicines 
and Medical Devices
https://www.anm.ro/en/ As required Yes
Spain [1] Spanish Agency of Medicines 
and Health Products 
(AEMPS), being part of the 
Spanish Ministry of Health
https://cima.aemps.es/cima/fichasTecnicas.
do?metodo=buscarDesabastecidos
As required (whenever 
a shortage is detected)
Yes
Slovenia Agency for Medicinal Products 
and Medical Devices (JAZMP), 
and Health Insurance Institute 
of Slovenia
http://www.jazmp.si/fileadmin/datoteke/seznami/
SFE/Prisotnost/Seznam_44_HUM_prenehanja_
motnje.pdf
www.cbz.si
Irregular Yes
United 
Kingdom
Specialist pharmacy service https://www.sps.nhs.uk/ As needed Yes
Uruguay Ministry of Public Health https://tramites.gub.uy/ampliados?id=2659 As needed Yes
US [2] Food and Drug Administration https://www.accessdata.fda.gov/scripts/
drugshortages/
Not specified Not
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simulate appropriate decision making in manufacturing and the 
trade of medicines, to highlight legal and economic frameworks, 
to disclose disincentives in the supply chain, as well as to reflect 
on best coping practices to help ensure patients’ health is not 
compromised by ongoing shortages.
At the EU level, in 2016, the EMA and the Heads of Medicines 
Agencies (HMA) created an HMA/EMA Task Force on the 
Availability of Authorized Medicines for Human and Veterinary 
Use, aiming to provide strategic support and advice to tackle 
disruptions in the supply of human and veterinary medicines 
and to ensure their continued availability (EMA, 2019). The 
key priorities of the HMA/EMA Task Force included i) looking 
at ways to minimize supply disruptions and avoid shortages; 
ii) developing strategies to improve prevention and management 
of shortages caused by disruptions in the supply chain; iii) 
encouraging best practices within the pharmaceutical industry to 
prevent shortages; iv) improving sharing of information and best 
practices among EU regulatory authorities to better coordinate 
actions across the EU, and v) fostering collaboration with key 
stakeholders and enhancing communication of supply problems 
to EU citizens. A set of documents was published by EMA to 
support regulators involved in coordinating shortage situations 
due to good manufacturing practice (GMP) non-compliance. 
A public catalogue for shortages has been established by EMA2, 
which is designed to communicate clear information on shortages 
to patients, health care professionals, and other stakeholders.
DISCUSSION
Studies Description
The studies included in this scoping review describe regional and 
countries contexts of medicine shortages and current perceptions 
of stakeholders, as well as their different perspectives. Indexed 
literature from the last 6 years presents important challenges, such 
as research on health and economic implications caused by supply 
disruptions and medicines shortages (Cousins, 2014; Steers, 2014; 
de Weerdt et al., 2017; Videau et al., 2019). More research efforts 
are needed to fully estimate the impact of medicine shortages on 
patients’ health especially in ambulatory care.
The descriptive cases reported from the US identified parenteral 
and hospital medicines with shortages episodes and their 
implications. Moreover, published studies for countries, including 
Brazil, help to estimate the health implications of shortages of 
essential antibiotics (Griffith et al., 2012; Galvao et  al., 2013; 
McKeever et al., 2013; Goldsack et al., 2014; Taylor et al., 2016; 
Mazer-Amirshahi et al., 2017). Next, efforts are needed to compare 
the current situation between country and regional levels.
Shortage Definitions and Global Context
Some ministries and health authorities have developed important 
initiatives to the timely identification of potential medicine 
shortages alongside initiatives to manage episodes of interruption 
2 European Medicines Agency—https://www.ema.europa.eu/en/human-
regulatory/ post-authorisation/medicine-shortages/shortages-catalogue
in the supply chain (Bocquet et al., 2017; Schwartzberg et al., 
2017; Administración Nacional de Medicamentos A y TMA, 
2018; CDER C for DE and research, 2018; INVIMA, 2018).
De Weerdt et al. (2015a) identified some elements included in 
the definitions, i.e., “supply,” “delivery,” “availability,” “permanent 
discontinuation of drugs,” and “time frame,” to consider 
a uniform definition for drug shortages among European 
countries. Definitions from Table 4 do not involve “delivery” 
and “availability” as these are not reflected in the current formal 
definitions. Instead, other common terms are included, such as 
“market” and “lack.”
Other countries, including France, Belgium, Italy, Spain, Brazil, 
and Colombia, have adopted definitions that include the perspective 
of shortage and some aspects related to supply chain management 
and market determinants. However, it is worth mentioning that the 
US FDA defines the problem of medicines shortage only from the 
perspective of scarcity and includes also a lead time. In addition, 
the US FDA, unlike other countries including Brazil and France, 
states that they will never ask a producer to make medicines or 
change the amount of medicines to be manufactured as solutions 
for dealing with drug shortages. They do not see this as their role 
(CDER C for DE and research, 2018).
A further finding is that a few countries have established 
a specific period into their definition to confirm the shortage 
situation: Australia, Belgium, France, Norway, and Uruguay 
(Bogaert et al., 2015; Bocquet et al., 2017; ISAGS, 2017; The 
Society of Hospital Pharmacists of Australian, SHPA, 2017; 
Bochenek et al., 2018). There are though some differences based 
on the perspective of the definition. Belgium, France, Norway, 
and Uruguay establish the shortage situation in a specific point of 
the supply chain, for instance, community pharmacies, or hospital 
pharmacies, or wholesalers. These countries have included 
periods for shortages, which varies from 72 h to 30 days (ISAGS, 
2017; Bochenek et al., 2018). On the other hand, Australia 
defined a period of 6 months considering the lack of a medication 
in the whole country (The Society of Hospital Pharmacists of 
Australian, SHPA, 2017). Uruguay uses a period less than 30 days 
as an “interruption of marketing” and more than 30 days as a 
“declaration of interruption of sale” (ISAGS, 2017).
One main feature of a specific shortage situation is the identity 
of the involved medicine, e.g., simvastatin (as an individual 
medicine) or the class of medicines (statins, lipid modulators). 
Shortages can also refer to a certain pharmaceutical form (e.g., 
injectable, capsule, or lotion), administration route (e.g., parenteral 
or oral), or a certain concentration or package size. The way the 
product episode is defined—broadly or narrowly—depends on the 
purposes of the analysis and the availability of information.
It should be highlighted that in 2017, a set of two co-existing 
definitions had been proposed by the WHO. On the supply 
side: “A ‘shortage’ occurs when the supply of medicines, health 
products and vaccines identified as essential by the health system 
is insufficient to meet public health and patient needs. This 
definition refers only to products that have already been approved 
and marketed, to avoid conflicts with research and development 
agendas.” On the demand side: “A ‘shortage’ will occur when 
demand exceeds supply at any point in the supply chain and 
may ultimately create a ‘stockout’ at the point of appropriate 
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service delivery to the patient if the cause of the shortage cannot 
be resolved in a timely manner relative to the clinical needs of 
the patient” (WHO, 2017). The needs of patients about essential 
medicines are an important link in these definitions.
The report of the Director General of the WHO presented at 
the last Assembly on global shortage of medicines and access to 
them in 2018 (A71/12) gives considerable relevance to situations 
that are recognized as a shortage of medicines, which coincide 
with those recently reported by South American countries 
(ISAGS, 2017; Organizaciòn Mundial de la Salud O, 2017). 
They show how different points of the medicines’ value chain are 
affected by concerns with demand, which are caused both by the 
lack of commercial attractiveness and by logistics, and supply 
factors that prevent having medicines in a timely manner.
In contrast, the title of the WHO’s report refers to the global 
scarcity of medicines, and throughout the document, the term 
“shortage” is being used (Organizaciòn Mundial de la Salud 
O, 2017). In general terms, the difference between the two 
terms (“scarcity of medicines” and “shortage of medicines”) 
can be minimal. However, it is worth specifying that “scarcity” 
refers only to those situations in which for a specific need the 
medication does not exist, whereas “shortage” covers those cases 
in which it is not possible to obtain the medicine in a timely 
manner. These latter problems are not solved by activities linked 
to research, development, and innovation.
Terms, such as “availability” and “affordability,” have also to be 
clearly distinguished to describe the shortage phenomena where 
these occur to avoid confusion and concentrate on appropriate 
activities to address the situation.
Regarding “availability,” at the jurisdiction/country level, this 
term usually implies that a medicine has marketing authorization 
and is marketed (can be bought or obtained from the health 
system). At the pharmacy level, this usually means that the 
medicine could be dispensed at demand or within a short period.
To contrast this, the term “affordability” refers to the extent 
the product is available at a reasonable price/cost for the patient 
or health care system considering the purchasing capacity of the 
individuals and/or the health system and does not endanger the 
financial sustainability of the purchasers. As mentioned earlier, 
this is particularly important for patients in LMICs where there 
are currently high co-payments. Affordability is also a growing 
issue in medium- to high-income countries especially with 
regard to new cancer medicines and those for orphan diseases 
with ever increasing prices (Howard et al., 2015; Godman et al., 
2017; Godman et al., 2018; Kwon et al., 2018).
The shortage of medicines is related to two main activities 
planned by the WHO to be implemented between 2019 and 
2023. These include i) research and development of medicines, 
and ii) supply chain management (States, 2019). Previous studies 
have reported essential medicines that need rapid solutions to 
address current concerns (ISAGS, 2017), i.e., the penicillins for 
syphilis and congenital syphilis.
The description of cases, the identified causes, and definitions 
of medicine shortages typically involve attributes that facilitate 
the identification of key solutions to address the main challenges 
of health conditions affected by the shortages. Currently, the 
specific actions described in the last version of WHO roadmap 
for 2019 to 2023 (States, 2019) do not discuss ways of approaching 
this and possible solutions to these cases, which is a concern.
We have highlighted the difficulty of building a simple 
typology of medicine shortages based on the multiple possible 
combinations of criteria. It may be more useful to define a 
checklist of relevant criteria that allows the characterization of 
the episode and to predict/estimate the potential impact/effects 
according to the likely magnitude and length of the shortage. 
This again will be researched further in the future.
Causes and Characteristics of the Context 
That Determines the Identified Episode
The causes and context that define the shortage episodes or 
interruptions in the supply chain are different from other areas 
of policy that affect medicine availability, such as the non-
availability of medicines without a marketing license, or those 
still in the research phase, or issues of affordability, leading to a 
lack of reimbursement or funding.
Overall, we believe medicine shortages can be defined 
according to several criteria (Figure 5).
In fact, medicine shortages might have multiple causes. Some of 
the causes might have a sequential cause-effect relationship, such 
as a reduction of future envisaged demand due to a reduction 
of the incidence of relevant diseases or reduced use due to the 
availability of new valued medicines, replacing existing ones, which 
will negatively impact on future profitability. This might cause the 
manufacturer to stop investing in the manufacturing process and 
disregard safety concerns, which may in turn lead to an increase 
in side effects and subsequent closure of the manufacturing plant.
Beyond an agreed single definition of medicine shortages, the 
concepts that could be developed must identify precisely the causes 
and points in the supply chain for which they apply. Topics, such 
as “shortage episode” could be more related to causes included 
in the market and policy dimensions (Table 2) or “interruption 
of supply chain episodes” for those situations caused or detected 
from the dimension of supply chain management.
Global Framework
Once a shortage episode is identified and characterized, including 
the population and health condition affected, the appropriate 
pharmaceutical and health policy tools, as well as rational 
management of medicines and their stocks, could help identify 
the most effective and efficient available intervention to address 
the problem. This could include fast tracking authorization and 
importation of the medicine or an equivalent from another 
country or recommending physicians to prescribe a substitute 
medicine; alternatively, potentially increasing reimbursed prices 
where profitability is a concern. Coordination of national efforts 
and international cooperation is urgently needed on various 
levels to address this, including UNASUR, the Andean Health 
Organization-Hipólito Unanue Agreement, the European Union, 
and the WHO. We will be following this up in the future as well.
There have been issues in Europe with older cancer medicines 
when the originator company has sold their molecule to a generic 
manufacturer, and this was re-launched at a considerably higher 
price, prompting potential counter measures (Pagliarulo, 2017; 
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Hawkes, 2017; Kahn, 2017; UK Department of Health and Social 
Care, 2016). Such activities will also be followed up, mindful of 
the need for manufacturers to make a profit for sustained supply.
Overall, we believe that specific strategies and solutions should 
be formulated at national and global levels. However, shortages 
must be clearly distinguished from scarcity. We believe this will lead 
to improved approaches to address episodes of medicine shortages 
and interruptions in the supply chain, as well as more pertinent 
solutions and their implementation to address current concerns.
There is a growing interest in international cooperation in 
the area of medicine shortages research, its prevention and 
ways to facilitate actions that provide a timely response. For 
South American countries, the development of a consensus 
to build or adapt a definition of medicines shortages demands 
the compilation of the countries’ definitions to generate a 
glossary related to logistics management and the availability of 
medicines. Some approaches, such as risk management and a 
panel of logistical indicators for medicines, can be adapted to 
each country according to its complexities, including the health 
system, epidemiological alerts, and geographical peculiarities. At 
the regional level, it has also been proposed to design a regional 
platform for horizon scanning and undertaking a pilot project to 
identify medicines that may be at risk of stock-outs, or possible 
withdrawals from the market, by reviewing the license status 
and reviewing databases related to imports and pharmaceutical 
market. No less important is to develop pilots for those priority 
medicines that are affecting the population health in the region.
Approaches to Medicine Shortages
The proposed categorization of causes of medicines shortages 
can be used as a guidance to find potential solutions, as well as 
considering the supply stage of medicines, market competition, 
and possible therapeutic substitutes.
The Ministries and Health Authorities must consider which 
health conditions are affected by the shortage or supply chain 
interruption. This includes the proposed therapeutic use of 
the medicine and the availability of other therapeutic options, 
considering the optimal treatment for the disease or health 
condition involved within available resources.
Maybe the most critical causes of medicine shortages are those 
related to market aspects because these situations depend on the 
will of the producer, seller, or buyer, and the power relationship 
between each part. Some common situations are when a 
pharmaceutical company decides to suspend the production of 
a medicine, or the seller decides to modify the price of a specific 
pharmaceutical product, affecting its funding and supply. In view 
of this, possible solutions cannot just be focused on new possible 
innovations.
Likewise, countries initiatives should not just consist only of 
designing and implementing systems to compile information about 
cases of medicine shortages. The specific interventions should be 
moved forward to address potential shortages, as stated earlier.
Other approaches could include designing and implementing 
of risk management programs that allow the anticipation of 
shortage episodes as well as implementing activities, including 
FIGURE 5 | Proposed criteria for different approach on medicines shortage.
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horizon scanning to identify “programmed obsolescence” of a 
medicine based on market withdrawals or changes in the pricing 
of products. We have seen horizon scanning and budgeting 
successfully used in countries to better plan for the future, with 
Sweden and exemplar for other countries (Wettermark et al., 
2010; Malmström et al., 2013; Eriksson et al., 2017; Godman 
et al., 2018), and these activities are likely to grow.
On the other hand, problems related to supply chain 
management are focused on logistics management and the 
level of the supply chain or network. These problems can be 
mitigated through the design of health care supply chains, with 
objectives that look to maximize the service level (availability and 
accessibility) and optimize the financial component, with recent 
changes in the public system in South Africa, a recent example 
among LMICs (Meyer et al., 2017). Ministries of Health should 
set key performance indicators for the country’s supply chain as 
well as implement improvements among the different agents in 
the supply chain over the different process including inbound 
and outbound transportation, fleet management, warehousing, 
materials handling, order fulfillment, logistics network design, 
inventory management, supply/demand planning, and the 
management of third-party logistics services providers (Council 
of Supply Chain Management Professionals (CSCMP), 2013). 
This will help reduce shortages in the future.
Some countries, such as France (Ordre National des 
Pharmaciens, 2015) have implemented actions focused on 
logistic aspects including defining a dead line to establish supply 
interruptions and length of shortage episodes. France also 
established a decree in 2012 to overcome the dysfunctions of 
the pharmaceutical distribution channel based on supply chain 
interventions, as well as introducing constraining and coercive 
measures for the various actors of the distribution channel. 
The decree defines shortages as the inability for a community 
or hospital pharmacy to deliver a medicine to a patient within 
72 h if the medicine is currently not available, as well as possible 
therapeutic alternatives if needed, or which supply difficulties 
may lead to a risk of public health for patients, thereby creating 
an emergency. France established a procedure whereby all the 
actors of the medicine’s distribution channel should join forces to 
help address current concerns. The decree also established some 
regulatory obligations for pharmaceutical companies, including 
ensuring an appropriate and continuous supply of medicines to 
wholesalers to meet public and patients’ needs, implementing 
emergency call centers to inform agents about an anticipated or 
a current medicine shortage, informing the French authorities 
of emergency supplies, specifying the quantities and addresses, 
and informing of any risk concerns associated with any medicine 
shortage. The wholesaler must also declare its distribution 
territory, meet public obligations, have a selection of medicines 
at least nine tenths of commercialized pharmaceutical products 
in France, and ensure to deliver medicines within 8 h from any 
request (Ordre National des Pharmaciens, 2015; Bocquet et al., 
2017). However, there are still challenges especially in the field 
of medicines with major therapeutic interest, and after 7 years of 
the introduction of the decree, there are still tensions between the 
different agents in the supply chain in France due to other causes 
not related to supply chain management (Biétry, 2018).
CONCLUSIONS
Descriptions of medicines shortage extracted from the multiple 
studies included in this scoping review allowed the authors to 
extract main characteristics, as well as contexts and reasons of 
medicines shortage, which medicines are involved, definitions of 
shortages, countries information systems on shortage reports and 
alerts management, and finally any networks between countries 
and stakeholders’ initiatives.
We believe this is first time such a comprehensive study has 
been undertaken reporting the most representative description 
of the current medicine shortage situation across multiple 
countries and giving inputs regarding national and global 
health policies related to the most frequent reasons reported 
for medicine shortages. This includes the description of the 
most likely medicine classes with shortages, current national 
definitions, and related terms and available databases to report 
medicine shortages. The study also describes frameworks and 
approaches among countries to help address these issues in 
the future. Overall, we believe our findings can help with the 
development of definitions related to the shortage of medicines 
that can be universally applied to prevent future confusion.
Signals linked with unattended or affected health conditions 
because of shortages must also be documented to establish 
effective interventions from a health authority perspective to 
ensure patients’ health is not compromised. Indeed, policy 
makers require solutions that prevent those cases in which the 
population’s health is affected by episodes of medicine shortages 
and/or interruption in the supply chain.
As part of this, we believe it is necessary to develop a consensus 
to build or adapt definitions of shortage and scarcity, as well as 
identifying all local definitions, to generate a glossary related to 
logistics management and the availability of medicines to facilitate 
aggregation of data from different sources and to better manage 
future situations. We have started this process with this article.
We also believe it is important to emphasize that for those 
cases where shortages are due to logistical and supply factors, and 
it is not possible to have the medicines in a timely manner, that 
potential ways forward are not related to improving research, 
development and innovation as some bodies are proposing. This 
is a very different situation, especially if alternative solutions are 
available including importation, as well as permitting increased 
prices if pertinent along with advocating and documenting 
possible alternatives, and these must be explored first.
Overall, we believe it would also be useful to identify options 
and best practices on how to address the most common causes of 
shortages and share these among all countries to provide future 
direction. These are research topics for the future building on this 
review across countries.
Our findings show that part of the problem of shortages is 
focused on provision, especially those cases related to the permanent 
suspension of production or voluntary suspension, due to, for 
instance, to the lack of commercial interest, either by low demand, 
end of the patent, price regulations, use of compulsory licenses 
and/or the introduction of new medicines. Regarding suspending 
commercialization, it is important to review specific cases that raise 
considerable public health concerns, such as antineoplastic and 
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antibiotics, to suggest potential ways to overcome the situation. We 
have started this process and will continue.
LIMITATIONS
Although the findings presented in this study allows us to make 
comparisons between countries related with, for instance, 
national definitions and involved medicines, there are other 
attributes that may well broaden the situation which we have not 
discussed. These can be addressed going forward.
RECOMMENDATIONS
Further research is needed to fully assess the clinical and economic 
impact of medicine shortages at different jurisdictional levels, 
including both hospital and ambulatory care levels. Additionally, 
cross-country and regional studies will help to identify current 
essential medicines supply disruptions and shortages episodes, 
which need prompt solutions.
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